The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Antimicrobial Therapy for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria

카바페넴 내성 그람음성균 감염의 항생제 치료

  • Wi, Yu Mi (Department of Internal Medicine, Sungkyunkwan University School of Medicine) ;
  • Kang, Cheol-In (Department of Internal Medicine, Sungkyunkwan University School of Medicine)
  • 위유미 (성균관대학교 의과대학 내과학교실) ;
  • 강철인 (성균관대학교 의과대학 내과학교실)
  • Published : 2018.10.01
⟨ Previous Next ⟩

Abstract

Carbapenem-resistance emerging in Gram-negative pathogens, such as Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, has become a major human health problem globally. The therapeutic options available for carbapenem-resistant pathogens are very limited. Antibiotics such as colistin, tigecycline, fosfomycin, and aminoglycosides are often the only ones that can be used to treat carbapenem-resistant pathogens. Carbapenem may still be an option in certain circumstances. The administration of combination therapy for carbapenem-resistant pathogens is controversial. This review presents the current knowledge of available antimicrobial therapeutic options for infections due to carbapenem-resistant pathogens in Korea.

Keywords

References

  1. Kang CI, Song JH. Antimicrobial resistance in Asia: current epidemiology and clinical implications. Infect Chemother 2013;45:22-31. https://doi.org/10.3947/ic.2013.45.1.22
  2. De Rosa FG, Corcione S, Pagani N, Di Perri G. From ESKAPE to ESCAPE, from KPC to CCC. Clin Infect Dis 2015;60:1289-1290. https://doi.org/10.1093/cid/ciu1170
  3. Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin Infect Dis 2006;42:657-668. https://doi.org/10.1086/499819
  4. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011;55:4943-4960. https://doi.org/10.1128/AAC.00296-11
  5. Iovleva A, Doi Y. Carbapenem-resistant enterobacteriaceae. Clin Lab Med 2017;37:303-315. https://doi.org/10.1016/j.cll.2017.01.005
  6. Kim YA, Park YS. Epidemiology and treatment of antimicrobialresistant gram-negative bacteria in Korea. Korean J Intern Med 2018;33:247-255. https://doi.org/10.3904/kjim.2018.028
  7. Kim D, Ahn JY, Lee CH, et al. Increasing resistance to extended-spectrum cephalosporins, fluoroquinolone, and carbapenem in gram-negative bacilli and the emergence of carbapenem non-susceptibility in Klebsiella pneumoniae: analysis of korean antimicrobial resistance monitoring system (KARMS) data from 2013 to 2015. Ann Lab Med 2017;37:231-239. https://doi.org/10.3343/alm.2017.37.3.231
  8. Rhee JY, Park YK, Shin JY, et al. KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. Antimicrob Agents Chemother 2010;54:2278-2279. https://doi.org/10.1128/AAC.00011-10
  9. Lee CS, Doi Y. Therapy of Infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother 2014;46:149-164. https://doi.org/10.3947/ic.2014.46.3.149
  10. Trecarichi EM, Tumbarello M. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence 2017;8:470-484. https://doi.org/10.1080/21505594.2017.1292196
  11. Bonomo RA, Burd EM, Conly J, et al. Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 2018;66:1290-1297. https://doi.org/10.1093/cid/cix893
  12. Karaiskos I, Souli M, Galani I, Giamarellou H. Colistin: still a lifesaver for the 21st century? Expert Opin Drug Metab Toxicol 2017;13:59-71. https://doi.org/10.1080/17425255.2017.1230200
  13. Gregoire N, Aranzana-Climent V, Magreault S, Marchand S, Couet W. Clinical pharmacokinetics and pharmacodynamics of colistin. Clin Pharmacokinet 2017;56:1441-1460. https://doi.org/10.1007/s40262-017-0561-1
  14. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of gram-negative pathogens: results from the SENTRY antimicrobial surveillance program (2006-09). J Antimicrob Chemother 2011;66:2070-2074. https://doi.org/10.1093/jac/dkr239
  15. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-3294. https://doi.org/10.1128/AAC.01733-10
  16. Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis 2017;64:565-571.
  17. Nation RL, Garonzik SM, Li J, et al. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis 2016;62:552-558. https://doi.org/10.1093/cid/civ964
  18. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant gram-negative bacteria. Expert Rev Anti Infect Ther 2013;11:1333-1353. https://doi.org/10.1586/14787210.2013.845523
  19. Lopez-Cortes LE, Cisneros JM, Fernandez-Cuenca F, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother 2014;69:3119-3126. https://doi.org/10.1093/jac/dku233
  20. Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother 2017;72:29-39. https://doi.org/10.1093/jac/dkw377
  21. Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. Int J Antimicrob Agents 2018;51:535-547. https://doi.org/10.1016/j.ijantimicag.2017.12.020
  22. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013;57:349-358. https://doi.org/10.1093/cid/cit253
  23. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 2018;18:391-400. https://doi.org/10.1016/S1473-3099(18)30099-9
  24. Satlin MJ, Chen L, Patel G, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother 2017;61:e02349-16.
  25. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014;58:654-663. https://doi.org/10.1128/AAC.01222-13
  26. Alexander EL, Loutit J, Tumbarello M, et al. Carbapenem-resistant enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis 2017;4:ofx063.
  27. Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010;138:1333-1339. https://doi.org/10.1378/chest.10-0463
  28. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis 2016;63:e61-e111. https://doi.org/10.1093/cid/ciw353
  29. Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME. Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: a systematic review and meta-analysis. J Infect 2018;76:321-327. https://doi.org/10.1016/j.jinf.2018.02.002
  30. Lee YJ, Wi YM, Kwon YJ, Kim SR, Chang SH, Cho S. Association between colistin dose and development of nephrotoxicity. Crit Care Med 2015;43:1187-1193. https://doi.org/10.1097/CCM.0000000000000931
  31. Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis 2013;75:331-336. https://doi.org/10.1016/j.diagmicrobio.2012.12.004
  32. Ni W, Han Y, Zhao J, et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents 2016;47:107-116. https://doi.org/10.1016/j.ijantimicag.2015.11.011
  33. Chuang YC, Cheng CY, Sheng WH, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC infect Dis 2014;14:102. https://doi.org/10.1186/1471-2334-14-102
  34. Cheng A, Chuang YC, Sun HY, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med 2015;43:1194-1204. https://doi.org/10.1097/CCM.0000000000000933
  35. De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 2014;18:R90. https://doi.org/10.1186/cc13858
  36. Sbrana F, Malacarne P, Viaggi B, et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013;56:697-700. https://doi.org/10.1093/cid/cis969
  37. Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011;55:5893-5899. https://doi.org/10.1128/AAC.00387-11
  38. Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2015;70:905-913. https://doi.org/10.1093/jac/dku432
  39. Thaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 2017;8:403-416. https://doi.org/10.1080/21505594.2016.1207834
  40. Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 2012;56:5744-5748. https://doi.org/10.1128/AAC.00402-12
  41. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010;16:184-186. https://doi.org/10.1111/j.1469-0691.2009.02921.x
  42. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014;20:862-872. https://doi.org/10.1111/1469-0691.12697
  43. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015;70:2133-2143. https://doi.org/10.1093/jac/dkv086
  44. Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2013;57:2907-2912. https://doi.org/10.1128/AAC.02365-12
  45. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011;17:1135-1141. https://doi.org/10.1111/j.1469-0691.2011.03553.x
  46. De Pascale G, Martucci G, Montini L, et al. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study. Critical Care 2017;21:173. https://doi.org/10.1186/s13054-017-1769-z
  47. Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect 2017;23:704-712. https://doi.org/10.1016/j.cmi.2017.09.001
  48. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation ${\beta}$-lactam/${\beta}$-lactamase inhibitor combinations. Clin Infect Dis 2016;63:234-241. https://doi.org/10.1093/cid/ciw243
  49. Wi YM, Greenwood-Quaintance KE, Schuetz AN, Ko KS, Peck KR, Song JH, et al. Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob Agents Chemother 2018;62:e01970-17.

Cited by

  1. Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem‐resistant Klebsiella pneumoniae isolates vol.34, pp.12, 2018, https://doi.org/10.1002/jcla.23506